Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.
- Authors
- Type
- Published Article
- Journal
- Circulation Research
- Publisher
- Ovid Technologies Wolters Kluwer -American Heart Association
- Publication Date
- Mar 30, 2012
- Volume
- 110
- Issue
- 7
- Pages
- 927–937
- Identifiers
- DOI: 10.1161/CIRCRESAHA.112.265140
- PMID: 22461363
- Source
- Medline
- License
- Unknown
Abstract
The (99m)Tc-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation.